Detalles de la búsqueda
1.
Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus.
Diabetes Obes Metab
; 18(6): 623-7, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26865535
2.
Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.
Diabetes Obes Metab
; 16(12): 1239-46, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25132212
3.
Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.
Diabetes Obes Metab
; 16(7): 613-21, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24400655
4.
Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.
Diabetes Obes Metab
; 15(10): 906-14, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23531118
5.
Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.
Diabetes Obes Metab
; 15(7): 668-73, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23489301
6.
Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.
Diabetologia
; 55(4): 915-25, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22237690
7.
Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
Diabetes Obes Metab
; 13(12): 1088-96, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21733058
8.
Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.
Int J Clin Pharmacol Ther
; 48(1): 46-58, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20040339
9.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
Diabetes Obes Metab
; 11(2): 167-76, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19125778
10.
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia.
Diabetes Obes Metab
; 11(12): 1145-52, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19758359
11.
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
Int J Clin Pract
; 63(1): 46-55, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19125992
12.
Migraine and migrainous stroke: risk factors and prognosis.
Neurology
; 43(12): 2473-6, 1993 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-8255442
13.
Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.
Bone Marrow Transplant
; 33(5): 543-8, 2004 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-14730342
14.
Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
J Clin Endocrinol Metab
; 97(5): 1615-22, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22419732
15.
Tacrolimus use in kidney-pancreas recipients is associated with less acute renal dysfunction than cyclosporine.
Transplant Proc
; 30(8): 4070-2, 1998 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-9865299
16.
The cost of rejection in liver allograft recipients.
Transplant Proc
; 30(4): 1500-1, 1998 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-9636610
17.
Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method.
Transplant Proc
; 30(5): 1701-5, 1998 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-9723249
18.
Nine-month follow-up of SangCya (Sang-35) in kidney transplant patients after conversion from Sandimmune.
Transplant Proc
; 31(1-2): 324-5, 1999.
Artículo
en Inglés
| MEDLINE | ID: mdl-10083127
19.
Sleep loss and nap effects on sustained continuous performance.
Psychophysiology
; 20(6): 643-51, 1983 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-6657852
Resultados
1 -
19
de 19
1
Próxima >
>>